Shares of NASDAQ APLS opened at $29.98 on Thursday ... the director now owns 100,000 shares of the company’s stock, valued at ...

Check the time stamp on this data. Updated AI-Generated Signals for Apellis Pharmaceuticals Inc. (APLS) available here: APLS.

Apellis Pharmaceuticals (NASDAQ:APLS) shares fell sharply on Tuesday after the Waltham, Massachusetts-based biotech reported lower-than-expected Q3 2024 financials as U.S. net sales from its eye ...

Short interest in Apellis Pharmaceuticals Inc (NASDAQ:APLS) increased during the last reporting period, rising from 15.26M to 21.09M. This put 23.91% of the company's publicly available shares short.

Apellis Pharmaceuticals Inc (NASDAQ:APLS) reported a 7% quarter-over-quarter growth in commercial development for its product, with 84,500 vials shipped. The company achieved a significant ...

The market expects Apellis Pharmaceuticals, Inc. (APLS) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024.

Apellis Pharmaceuticals, Inc. (APLS) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $1.17 per share a year ago.

Evercore ISI analyst Umer Raffat maintained a Buy rating on Apellis Pharmaceuticals (APLS – Research Report) today. The company’s shares closed yesterday at $27.71. According to TipRanks ...